| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Glen Hazlewood | Q56797844 |
| Ashwin N Ananthakrishnan | Q87620654 | ||
| P2093 | author name string | L Peyrin-Biroulet | |
| A Cholapranee | |||
| G G Kaplan | |||
| P2860 | cites work | Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 |
| Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease | Q24242101 | ||
| Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis | Q24245033 | ||
| Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease | Q24247745 | ||
| Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews | Q24289190 | ||
| Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis | Q43553836 | ||
| Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis | Q44166494 | ||
| Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis | Q46184125 | ||
| Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis | Q46286038 | ||
| Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis | Q46990369 | ||
| Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. | Q51739537 | ||
| Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. | Q51868985 | ||
| Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
| Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis | Q57910344 | ||
| Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | Q59120396 | ||
| Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings | Q79902964 | ||
| Does mucosal healing impact patient outcomes long-term? | Q80607501 | ||
| Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease | Q82657632 | ||
| Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial | Q83161262 | ||
| Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI | Q84563498 | ||
| Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis | Q87263251 | ||
| Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis | Q27006683 | ||
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? | Q28251305 | ||
| The burden of inflammatory bowel disease in Europe | Q28285200 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis | Q30300234 | ||
| The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? | Q34147687 | ||
| Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial | Q34156631 | ||
| Vedolizumab as induction and maintenance therapy for ulcerative colitis | Q34365566 | ||
| Vedolizumab as induction and maintenance therapy for Crohn's disease | Q34365574 | ||
| Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis | Q35171236 | ||
| Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis | Q36173188 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol | Q36550808 | ||
| Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? | Q36763425 | ||
| Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis | Q37585946 | ||
| Anti-TNF therapy in inflammatory bowel diseases: a huge review. | Q37756516 | ||
| Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease | Q37937180 | ||
| Mucosal healing in inflammatory bowel diseases: a systematic review | Q38030351 | ||
| Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies | Q38125012 | ||
| Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. | Q38186069 | ||
| Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease | Q38205873 | ||
| Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis | Q38274057 | ||
| Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. | Q38572827 | ||
| Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease | Q38647797 | ||
| Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis | Q38717552 | ||
| Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. | Q38895063 | ||
| C-reactive protein and monitoring the activity of Crohn's disease. | Q39344634 | ||
| Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort | Q40186159 | ||
| Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs | Q41238509 | ||
| Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials | Q41822229 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Crohn's disease | Q1472 |
| ulcerative colitis | Q1477 | ||
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 1291-1302 | |
| P577 | publication date | 2017-03-22 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials | |
| P478 | volume | 45 |
| Q55512054 | A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn’s Disease. |
| Q47258474 | A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease |
| Q93355924 | A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases |
| Q42044847 | Access to biologicals in Crohn's disease in ten European countries |
| Q92511318 | Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease |
| Q99587556 | Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis |
| Q47142918 | Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease. |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q64885429 | Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. |
| Q47192581 | Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease |
| Q91658189 | Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study |
| Q92324983 | Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study |
| Q92714696 | Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience |
| Q48315875 | Editorial: biologics in inflammatory bowel disease-time for direct comparisons |
| Q48228653 | Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? |
| Q58706830 | Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers |
| Q92081099 | Effects of anti-TNF-α in experimental diversion colitis |
| Q91994732 | Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses |
| Q92775683 | Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment? |
| Q90592475 | Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation |
| Q57031312 | Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease |
| Q64286948 | Fluorescence-based tracing of transplanted intestinal epithelial cells using confocal laser endomicroscopy |
| Q64062261 | Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? |
| Q58707093 | Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis |
| Q64121962 | Infliximab in inflammatory bowel disease |
| Q47309441 | Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? |
| Q90075166 | Long-Chain Polyphosphate Is a Potential Agent for Inducing Mucosal Healing of the Colon in Ulcerative Colitis |
| Q92970079 | Meta-analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis |
| Q38670811 | New treatment strategies for ulcerative colitis |
| Q91970764 | Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor |
| Q88813328 | Overall and Subgroup Prevalence of Crohn Disease Among Patients With Hidradenitis Suppurativa: A Population-Based Analysis in the United States |
| Q55432449 | Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. |
| Q46345854 | Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis |
| Q91706522 | Targeting Mucosal Healing in Crohn's Disease |
| Q64120184 | The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis |
| Q89450520 | The state of the art on treatment of Crohn's disease |
| Q88288521 | Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease |
| Q52603361 | Therapy for Crohn's Disease: a Review of Recent Developments. |
| Q92875750 | Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process |
| Q52614638 | Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A. |
Search more.